Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Corcept Therapeutics (CORT) EBITDA: 2009-2024

Historic EBITDA for Corcept Therapeutics (CORT) over the last 12 years, with Dec 2024 value amounting to $137.0 million.

  • Corcept Therapeutics' EBITDA fell 78.07% to $10.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $65.6 million, marking a year-over-year decrease of 54.26%. This contributed to the annual value of $137.0 million for FY2024, which is 27.66% up from last year.
  • As of FY2024, Corcept Therapeutics' EBITDA stood at $137.0 million, which was up 27.66% from $107.3 million recorded in FY2023.
  • Corcept Therapeutics' 5-year EBITDA high stood at $137.0 million for FY2024, and its period low was $106.2 million during FY2020.
  • Over the past 3 years, Corcept Therapeutics' median EBITDA value was $112.6 million (recorded in 2022), while the average stood at $119.0 million.
  • Per our database at Business Quant, Corcept Therapeutics' EBITDA fell by 4.75% in 2023 and then climbed by 27.66% in 2024.
  • Over the past 5 years, Corcept Therapeutics' EBITDA (Yearly) stood at $106.2 million in 2020, then grew by 5.37% to $111.9 million in 2021, then grew by 0.68% to $112.6 million in 2022, then dropped by 4.75% to $107.3 million in 2023, then rose by 27.66% to $137.0 million in 2024.